William Werkmeister, Author at NFCR

William Werkmeister

Novel CAR-T Treatment Approved for Second Indication

In the past two months, the FDA has approved a revolutionary new form of immunotherapy, called chimeric antigen receptor (CAR) T cell therapy, for two blood cancers: B cell acute lymphoblastic leukemia (ALL) in August, 2017 and now on October 18th, for aggressive diffuse large B cell lymphoma (DLBCL), a…...

Read more